Mothers who have big babies may have had abnormal glucose tolerance during pregnancy. Glycosylated haemoglobin (HbA,) concentrations were measured on the first or second day after delivery in 50 women who had had babies weighing over the 95th centile for gestational age and in 50 women who had had normal-sized babies (controls). Nine of the mothers of big babies but only one of the controls had an HbA, concentration above the normal range. All the women had normal glucose tolerance and HbA1 concentrations six weeks after delivery.
Introduction
The delivery of a large baby may indicate that the mother had abnormal glucose tolerance during pregnancy. In the gestational diabetic, by definition, glucose tolerance returns to normal after delivery. It is therefore not possible to confirm the diagnosis retrospectively by conventional measures of carbohydrate metabolism.
Method
Glycosylated haemoglobin was measured by a modification of the method of Kynoch and Lehmann2 3on the first or second day after delivery in 50 mothers who had had babies weighing over the 95th centile for gestational age. 4 Glycosylated haemoglobin was also measured at the same time in a control group of 50 mothers who had had a baby weighing between the 10th and 90th centile for gestational age. The normal range for non-diabetic adults for this method in our laboratory is 5-6-800% (mean 6-8, SD 0 6). Women with insulindependent diabetes and those known to have abnormal glucose tolerance were excluded from both the study and the control series.
Six weeks after delivery a 50-g oral glucose tolerance test was carried out in all women who had had a large baby, and HbA1 measurement was repeated. Plasma glucose was measured by a glucose oxidase method using a Technicon autoanalyzer. The World Health Organisation (1965) criteria were used and a fasting or 2-hour concentration below 7-4 mmol/l (133 mg/100 ml) was considered to be normal.
Results
Nine of the women who had had large babies had an HbA1 concentration on the first or second day after delivery above the normal range for our laboratory. The mean concentration (± SD) for the women who had had big babies was 7-28 ±0-8%. All except one ofthe women who had had normal-sized babies had an HbA1 concentration 
SHORT REPORTS Seatone is ineffective in rheumatoid arthritis
Seatone is an extract of the New Zealand green-lipped mussel Perna canaliculus. It has been found to have anti-inflammatory activity in an experimental model' and has been enthusiastically reported in newspapers.2 A controlled clinical trial has been reported,3 suggesting that the green-lipped mussel is effective in rheumatoid arthritis and osteoarthritis while having a low incidence of side effects. Our study was designed to test the anti-inflammatory efficacy of a single course of four weeks' treatment with Seatone.
Patients, methods, and results
Thirty outpatients with rheumatoid arthritis took part in a cross-over study to compare Seatone 300 mg with an identical placebo capsule three times daily. The placebo capsule consisted of dried fish and had an offensive smell indistinguishable from that of Seatone. Each treatment was given for four weeks and was added to the patients' existing drug regimen. The order of treatment was randomised and balanced. The patients were receiving various analgesic and anti-inflammatory drugs but these had been constant for at least four weeks before the start of the study and remained constant during the study. All patients had arthritis that was inadequately controlled by existing treatment, and all had requested a trial course of Seatone in response to an advertisement in the waiting area of the clinic.
Note was made at the start of the study and at the end of each treatment period of the pain score, using a visual analogue scale, duration of morning stiffness, articular index, proximal interphalangeal joint circumference, and analgesic requirements. Preference for one or other treatment period was measured at the end of the study, when side effects were recorded. The results were analysed using Student's t test applied to paired data, except for the duration of morning stiffness and preference, which were analysed using the Wilcoxon test. Twenty-six patients completed the study. The table summarises the results. There were no significant differences between Seatone and placebo in any measurement. Ten patients preferred Seatone, nine preferred placebo, and seven had no preference.
All the patients had requested Seatone treatment, so it is not surprising that several responded well. Thirteen out of 22 patients (59 %) with morning stiffness at the start of the study noted a substantial reduction in its duration, and in two cases it disappeared completely. Figures for the placebo group were identical. One patient was so enthusiastic about the first period of treatment that she returned her stick to the physiotherapy department; she Means 
